The advent of immunotherapy, notably immune checkpoint inhibitors (ICI) such as PD - 1/PD-L1 antibodies, has revolutionized cancer treatment by harnessing the power of the immune system to target cancer cells (3, 4). The gene discussed is RPL17; the disease is cancer.